EyePoint said its experimental drug to treat a serious eye disease that affects older people failed in a late-stage trial, sending its shares plunging over 65% in premarket trading on Monday.
The company was testing the drug, Duravyu, against approved treatment Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss.